Address
No. 4 The Forum
Saint Helier, JE2 4UF
United States of America (the)
Phone
44 15 3475 6700
Website
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Employees
1488
First IPO Date
October 01, 2015
| Name | Title | Pay | Year Born |
| Frank Leonard | Chief Executive Officer & Director | 974,316 | N/A |
| Barak Ben Arye | General Counsel | 796,075 | 1977 |
| Michael Puri | Chief Human Resources Officer | 932,882 | 1969 |
| Mukund Paravasthu | Chief Operating Officer | 965,560 | 1970 |
| Uri Weinberg | Chief Innovation Officer & Chief Medical Officer | 1.16M | 1979 |
| Christoph Brackmann | Chief Financial Officer | 1.16M | 1974 |
| William F. Doyle | Executive Chairman | 1.78M | 1962 |
| Adam Daney | Head of Investor Relations | 0 | N/A |
NovoCure Limited operates as an oncology enterprise specializing in the development, manufacturing, and global commercialization of its proprietary Tumor Treating Fields (TTFields) technology. These innovative devices are engineered to treat solid tumor cancers, with the company's market presence spanning the United States, Europe, the Middle East, Africa, Japan, and Greater China. The company's commercialized offerings include Optune, which is indicated for glioblastoma, and Optune Lua, approved for use in malignant pleural mesothelioma. Beyond these established treatments, NovoCure actively conducts, or has completed, clinical research into the potential applications of TTFields for a broader spectrum of cancers. These investigational areas encompass brain metastases, gastric cancer, further studies in glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. Founded in 2000, NovoCure Limited is headquartered in Saint Helier, Jersey.